Sir: The neuroleptic malignant syndrome is a rare idiosyncratic drug reaction comprising muscular rigidity, altered consciousness and autonomic dysfunction, which has been described following the administration of major tranquillisers such as butyrophenones, thioxanthenes and phenothiazines. ' 2 It is thought to be due to dopamine receptor blockade in the basal ganglia and hypothalamus.2 We describe a patient who developed the neuroleptic malignant syndrome after metoclopramide therapy.
A 53-year-old Jamaican man was given 20 mg of metoclopramide by intramuscular injection for nausea during an acute illness characterised by pyrexia and productive cough. Three days later he noticed stiffness and weakness of his legs; over the next week he became increasingly immobile and tremulous, with difficulties in swallowing, speaking and breathing, and frequent bouts of sweating. On While taking acetazolamide her speech was no different from the postmenstrual state. Opsoclonus was absent. The myoclonic jerks were infrequent at rest and were markedly reduced in amplitude and incidence during intentional motion. Efficacy continued for five consecutive cycles without side effects. A double-blind placebo trial during the next menstrual period was aborted on the second day as she became bedridden with myoclonus. Several hours after starting acetazolamide she improved. The next menstrual cycle went smoothly with this medication. Valproic acid serum levels were unchanged with the addition of acetazolamide.
Catamenial exacerbation of action myoclonus has been described.7 The mechanism is not apparent. The patient previously described underwent bilateral oophorectomy and worsened. ' 
